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INTRODUCTION
Life threatening hemorrhage due to thrombocytopenia
remains a major cause of morbidity and mortality following
hematopoietic stem cell transplantation [1]. The use of
platelet transfusions to avoid or treat serious hemorrhage is
associated with a number of risks including infections, aller-
gic reactions, allosensitization, and increasing costs [2–5].
Prolonged thrombocytopenia has particularly been a prob-
lem following sibling and unrelated donor umbilical cord
blood transplantation (UCBT) [6,7]. The mean time to
platelet engraftment after umbilical cord blood transplanta-
tion has been approximately 60–70 days compared to 10–15
days for peripheral blood stem cell transplantation and
15–25 days for bone marrow transplantation [7–10].
Several potential hypotheses could explain the pro-
longed time to platelet engraftment following UCB trans-
plantation. There could be a quantitative deficit in mega-
karyocyte and platelet (MK/plt) progenitors in the UCBT
inoculum. This could be due to the small collection volumes
or to a decreased proportion of MK/plt progenitors relative
to peripheral blood stem cell or bone marrow transplant
inoculum. MK/plt progenitors in UCB could also have
functional deficits such as a decreased responsiveness to
thrombopoietic growth factors or to the bone marrow
microenvironment of the transplant recipient. Allogeneic
UCB MK/plt progenitors or their progeny could be
particularly sensitive targets of immune-mediated
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ABSTRACT
Optimizing platelet engraftment following hematopoietic stem cell transplantation is essential for minimizing trans-
plant-related morbidity, particularly following umbilical cord blood transplantation (UCBT), where platelet engraft-
ment frequently takes .60 days. One strategy for optimizing platelet engraftment following UCBT is to study or
alter the genetic program of megakaryocyte/platelet (Mk/plt) progenitors. Retroviral vector gene transfer has previ-
ously proven useful for studying the biology of hematopoietic stem cells; however, procedures for transducing UCB
cells of the Mk/plt lineage with retroviral vectors have not been described. We report here that Mk/plt progenitors
generated from UCB progenitors can be efficiently transduced with retroviral vectors. Transduced Mk/plt cells
were identified and quantitated by expression of a vector transgene encoding a truncated version of the human
nerve growth factor receptor (NGFR). Vector-mediated NGFR expression could be readily detected in Mk/plt pro-
genitors defined by immunophenotypic, morphologic, and functional criteria. In addition, NGFR expression persist-
ed in mature anucleate platelets generated from the transduced Mk/plt progenitors. These methods may be useful
for introducing genetic elements into Mk/plt progenitors to study various aspects of platelet development and biol-
ogy and for marking ex vivo expanded Mk/plt progenitors to determine their contribution to engraftment.
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destruction.Currently, it remains unclear whether any or all
of these mechanisms play a role in the delay in platelet
engraftment that occurs following UCBT.
Retroviral vector gene transfer provides a potentially
useful strategy for defining the mechanisms underlying the
delay in platelet engraftment following UCBT. For exam-
ple, retroviral vector gene transfer could be used to intro-
duce genetic elements into UCB Mk/plt progenitors to
study their role in platelet engraftment and development
[11]. In addition, retroviral vector-mediated gene transfer
could be used to genetically mark ex vivo expanded hemato-
poietic stem cells or progenitors in order to determine
whether they enhance MK/plt engraftment [12,13]. To date
however, reagents and procedures designed specifically to
gene-mark Mk/plt progenitors as well as mature platelets
have not been described. In the current report, we demon-
strate that MK/plt progenitors can be efficiently transduced
with retroviral vectors and that the vector transgene prod-
uct can persist in mature anucleate platelets.
MATERIALS AND METHODS
Isolation of CD341Lin– cells from UCB 
Fresh UCB was collected into adenosine-citrate-dex-
trose (ACD) in sterile bottles at the time of delivery. The
UCB was then diluted 1:2 with Dulbecco’s phosphate
buffered saline (PBS), and red-cell separation was per-
formed at room temperature using 6% Hespan (DuPont
Pharma, Wilmington, DE) as previously described [14].
Residual red cells were hemolysed with 0.17 M NH4Cl con-
taining 10 mM Tris-HCl ND 200mM EDTA, pH 7.2. To
enrich for CD341Lin– cells in UCB, mononuclear cells
were reconstituted to a concentration of 2–83107 cells/mL
in Iscove’s modified Dulbecco’s medium/1% bovine serum
albumin (IMDM/1% BSA). Cells were immunolabeled with
an antibody cocktail (anti-glycophorin A, anti-CD3, anti-
CD2, anti-CD56, anti-CD24, anti-CD19, anti-CD14, anti-
CD16, anti-CD66b) (StemCell Technologies, Vancouver,
BC, Canada) followed by magnetic colloid separation using
a StemSep device according to device instructions. The
resulting CD341Lin– cells were collected into IMDM/1%
BSA.
Ex vivo expansion and retroviral vector transduction of
CD341Lin– cells 
CD341Lin– cells were placed in suspension culture
with serum-free BIT 9500 (StemCell Technologies) sup-
plemented with Flt-3-ligand (Flt-3-L, 5 ng/mL)
(Immunex, Seattle, WA), interleukin (IL)-3 (1 ng/mL) and
thrombopoietin (TPO) (2.5 ng/mL) (both from R&D Sys-
tems, Minneapolis, MN). After 72 hours of cytokine stim-
ulation, cells were transduced with the retroviral vector
MN which expresses a truncated version of the nerve
growth factor receptor (NGFR) as a marker gene [14,15].
MN vector supernatant was prepared as previously
described [14]. For transduction, MN viral supernatant
was added at 25% final volume along with protamine sul-
fate (Eli Lilly, Indianapolis, IN) at 4 mg/mL to 53105
CD341Lin– UCB cells/mL. The cells were then cen-
trifuged at 1200 g for 90 minutes and then placed in a
humidified 378C/5% CO2 incubator.
Analysis of cultured and transduced MK/plt progenitors
Flow cytometric analysis. Three days after exposure to
MN, cells were stained with anti-CD34-Cy (clone HPCA-
2) (Becton Dickinson), anti-CD61-FITC, anti-CD41-PE
(clone P2) (Immunotech, Westbrook, ME), and anti-
NGFR-FITC or PE (clone ATCCHB8737) (Chromoprobe,
Mountain View, CA) to determine the frequency of NGFR1
cells within the total CD341, CD341CD611, and
CD341CD411 populations.
Morphologic analysis. To determine whether gene transfer
had occurred into MK/plt progenitors defined by morpho-
logic criteria, UCB cells were sorted to purity 48 to 72
hours after exposure to MN on the basis of NGFR expres-
sion using a FACStar Plus apparatus (Becton Dickinson).
The recovered cells were cytospun onto slides, stained with
Wright-Giemsa, and analyzed for phenotypic features typi-
cal of various stages of platelet development.
Analysis of gene transfer into CFU-megakaryocytes (CFU-
MK). Gene transfer into clonogenic megakaryocyte pro-
genitors was evaluated by sorting NGFR1 transduced
CD341Lin– UCB cells to purity with flow cytometry. Sorted
cells were then placed into serum-free MegaCult colony
assays (Stem Cell Technologies) and grown for 21 days at
378C in a humidified incubator. To determine if any of the
sorted NGFR1 cells had generated CFU-MK, colonies
were stained in situ with anti-CD41 according to MegaCult
kit instructions.
Analysis of platelets generated in vitro from transduced
Mk/plt progenitors
To determine whether NGFR expression persisted in the
platelet progeny of transduced stem cells and progenitors,
MN-transduced CD341Lin– UCB was cultured for 11 days
in the same media used in the ex vivo cultures described
above. Recombinant human (rh)IL-11 at 12.5 ng/mL (Gen-
zyme, Boston) was added for the final 24–48 hours to
enhance platelet production. Cells were then analyzed by
flow cytometry for expression of NGFR on platelets.
Platelets were defined as events with low forward and side
scatter that were CD45– and CD411. In control experiments,
flow cytometric analysis of pure platelet concentrates was
performed to define the appropriate platelet gate. 
RESULTS
Ex vivo expansion of Mk/plt progenitors from UCB
Based on preliminary experiments (data not shown),
CD341Lin– UCB cells were cultured in serum-free condi-
tions supplemented with Flt3-L/IL-3/TPO to expand Mk/plt
progenitors. In these studies, Mk/plt progenitors were
defined as cells that coexpressed the platelet glycoproteins
CD41 or CD61 along with the stem cell marker CD34 [16].
Fluorescence-activated cell sorting (FACS) analysis of cul-
tures after 7 days demonstrated that substantial expansions of
cells with the high forward and side scatter properties and
morphologic appearance typical of megakaryocytes had
occurred (Figure 1A and B and data not shown). In addition,
expansion of the total number of CD341, CD341CD411, and
CD341CD611 cells had occurred (Figure 1 and Table 1). A
number of CD34–CD411 and CD34–CD611 cells, which
were presumably more mature Mk/plt progenitors than their
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CD341 counterparts, were noted as well (Figure 1D and 1F
respectively) [16]. Taken together, these results indicate that a
variety of Mk/plt progenitors at various stages of develop-
ment can be readily generated from CD341Lin– UCB cul-
tured for 1 week in Flt3-L/IL-3/TPO.
Retroviral vector gene transfer occurs efficiently and
stably into MK/plt progenitors
We next sought to transduce the ex vivo expanded UCB
by exposing the CD341Lin– UCB to the MN retroviral vec-
tor during the culture process. As previously described, MN
expresses a truncated version of the human NGFR as a
marker of transduced cells [14,15]. To determine whether
gene transfer had occurred into MK/plt progenitors, several
strategies were pursued. First, transduced cells were analyzed
with flow cytometry to determine whether the marker gene
was expressed in CD341Lin– UCB cultured for 1 week in
Flt3-L/IL-3/TPO. The NGFR marker could be readily
detected in the cultured UCB, and the mean gene transfer
efficiency in the total cell population was 13% 6 3% (mean
6 SEM; n=5) (Figure 2). Next, multiparameter flow cyto-
metric analysis for the expression of NGFR in cells express-
ing markers of platelet development was performed. Highly
efficient gene transfer was noted in the CD341CD411 and
CD341CD611 subpopulations (Figure 3) as well as in the
CD34–CD411 and CD34–CD611 subpopulations (data not
shown). In all populations analyzed, the larger, presumably
more mature MK/plt progenitors (corresponding to region
R3 in Figure 2A), consistently demonstrated higher levels of
gene transfer (see Figures 2D, 3D, and 3H) than the blast-
sized cells (corresponding to region R2 in Figure 2A), which
were presumably more primitive (see Figures 2B, 3C, and
3G). To confirm that the NGFR marker was stably expressed
in Mk/plt progeny of the transduced UCB, CD611NGFR1
cells were isolated to purity by flow cytometry 72 hours after
transduction. These cells were then placed into serum-free
culture for 15 additional days in the presence of Flt-3/IL-
3/TPO and reanalyzed for the continued expression of
NGFR. A mean of 76% (range 74–79%) of the progeny of
the sorted CD611NGFR1 population continued to express
high levels of NGFR (n=2), confirming that NGFR was sta-
bly expressed in cells of the Mk/plt lineage.
To further confirm that Mk/plt progenitors had been
transduced, NGFR1 cells were sorted to purity from both
the blast window and the large cell window (Regions R2 and
R3 respectively in Figure 2A) and examined microscopically
(Figure 4A–C). The NGFR1 cells isolated from the blast
window were 75–84% nonspecific blast cells with an
increased N:C ratio, dispersed nonclumped chromatin, and
cytoplasmic vacuolization typical of primitive progenitors.
Proplatelet morphology was observed in 7–19% of the blast
cells. Multiple nuclear lobes, a specific morphologic feature
of mature megakaryoctyes, were observed in 1–2% of cells.
The NGFR1 cells isolated from the large cell window
included 33–60% blasts, 21–39% macrophages, 3–6 % pro-
platelets, and 12–24% cells with multiple nuclear lobes.
Based on these morphologic criteria, gene transfer appeared
to have occurred into both early progenitors and committed
MK/plt progenitors.
As an additional confirmation that gene transfer had
occurred in Mk/plt progenitors, gene transfer into CFU-
MKs was also analyzed. Transduced NGFR1 UCB cells
were sorted to purity, plated in an agarose-based CFU-MK
assay, and analyzed for the presence of CFU-MK by in situ
staining of the resulting colonies for surface expression of
the Mk/plt specific marker gpIIb/IIIa. An average of 29%
(n=3, range 21–44%) of colonies generated from the sorted
NGFR1 cells were CFU-MK (Figure 4D). In addition,
Figure 1. Ex vivo expansion of UCB progenitors
CD341Lin– cord blood cells were cultured with Flt3-L/IL-3/TPO for 7 days
as described in Materials and Methods. The starting CD341Lin– cord blood
cells are depicted in panels A (scatter), C (CD34 vs. CD41) and E (CD34 vs.
CD61) and the expanded cells are depicted in panels B, D, and F. The data
are representative of five experiments.
Table 1. Ex vivo expansion of UCB




The fold expansion (mean 6 SEM) of progenitors from CD341Lin– UCB
cells cultured in Flt-3-L/IL-3/TPO for 7 days was calculated by multiplying
the absolute cell number in each culture by the percent of positive events in the
upper right quadrant in Figure 1E–F (n=5).
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Figure 2. Retroviral vector gene transfer in UCB expanded in Flt-3L/IL3/TPO
CD341Lin– cord blood cells were cultured with Flt3-L/IL3/TPO and transduced with MN as described in Materials and Methods. Panel A demonstrates the
gates used to identify the total population (R1), the blast cells (R2) and the large cells (R3). Panels B–D demonstrate the gene transfer efficiency in the total cell
population (B), the blast cells (C) and the large cells (D). The gene transfer efficiency is determined by the proportion of NGFR1 cells. The cursors were set for each
population so that ,1% of mock-infected controls were NGFR1. The FACS data is representative of five experiments. The mean gene transfer efficiency (6
SEM) of all 5 experiments is presented above the cursors in B–D.
Figure 3. Retroviral vector gene transfer into Mk/plt subsets
Multiparameter FACS analysis was performed on MN-transduced CD341Lin– cord blood cells to determine the gene transfer efficiency in cells expressing Mk/plt
markers. The dotted lines represent mock-infected controls. The gene transfer efficiency was determined in CD341CD411 cells (A–D) and CD341CD611 cells
(E–H). The gene transfer efficiency was determined in the total CD341CD411 cells (B) and total CD341CD611 cells (F), the intermediate blast cell subset of the
CD341CD411 cells (C) and total CD341CD611 cells (G), and the large cell subset of the CD341CD411 cells (D) and total CD341CD611 cells (H). The total,
blast cell, and large-cell subsets were gated as described in Figure 2. The FACS data is representative of five experiments; while the mean gene transfer efficiency
(6 SEM) of all five experiments is presented above the cursors in panels B–H.
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many of these colonies contained large cells typical of mega-
karyocytes. In situ staining for NGFR expression revealed
that approximately 30% of the CFU-MK continued to
express NGFR. In total, these observations further confirm
that gene transfer had successfully occurred into MK/plt
progenitors.
Platelet progeny of transduced progenitors express NGFR
In many gene transfer studies designed to elucidate
aspects of Mk/plt biology and development, persistence of
the vector transgene product in mature anucleate platelets
would be important. In addition, in a clinical trial involving
transplantation of ex vivo expanded gene-marked UCB, one
useful endpoint would be detection of the genetic marker
on mature platelets in the peripheral blood. To test whether
NGFR could be detected on platelet progeny of the trans-
duced MK/plt progenitors, CD341Lin– UCB was trans-
duced with MN in Flt-3/IL-3/TPO. rhIL-11 was then
added to the cultures 1 to 2 days prior to analysis in order
to further enhance the production of proplatelets and
platelets [17]. Flow cytometric analysis was then performed
to specifically analyze NGFR expression in platelets by gat-
ing on CD45–CD411 events with the scatter properties of
platelets. A mean of 28% (range 19–39%; n=3) of the
platelets generated in these cultures were NGFR1 (Figure
5C), demonstrating that NGFR expression persisted
through the maturation of MK/plt progenitors into mature
platelets. 
DISCUSSION
Over the last several years, retroviral vector gene trans-
fer has been widely used in the study of hematopoiesis. For
example, a number of groups have used retroviral vectors to
introduce putative oncogenes, cytokines, and cytokine
receptor genes into hematopoietic cells to study their bio-
logic roles [11,18–20]. In murine transplant models, retrovi-
ral vector gene transfer has been used to mark putative stem
cells to delineate their role in engraftment [21]. Primate and
human transplant studies have been performed that utilized
retroviral vector gene transfer to determine whether stem
Figure 4. Gene-modified ex vivo expanded UCB cells demonstrate
Mk/plt progenitor morphology
CD341Lin– cord blood cells were transduced with MN, and then NGFR1 cells
were isolated to purity by flow cytometry 48 hours later. Cytospins of these cells
were prepared and stained with Wright-Giemsa. Many NGFR1 cells demon-
strated the presence of characteristic MK/plt progenitor morphologic features
including nuclear endoreduplication (A–C); proplatelet processes (B), and
demarcation zones (C). 
Gene modified expanded UCB can give rise to CFU-MK
In separate experiments CD341Lin– cord blood cells were transduced with
MN and then NGFR1 cells were isolated to purity and placed in CFU-MK
assays. CFU-MK were then detected by in situ staining for CD41 which
demonstrated that the NGFR1 cells could generate CFU-MK (D). Data are
representative of three experiments.
Figure 5. The MN gene product is expressed on platelet progeny of transduced progenitors 
CD341Lin– cord blood cells were transduced with MN and then cultured further with Flt3-L/IL3/TPO/IL-11 to generate mature platelets as described in Mate-
rials and Methods. Platelets defined by gating through R1 in A and R2 in B demonstrated high levels of NGFR expression (solid-bold line in C). Mock-infected
control platelets are represented by the dotted line in panel C. The data are representative of three experiments.
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cells contributing to engraftment could be expanded ex vivo
[12,13,22,23].
In the current report, we describe the development of
procedures for using retroviral vector gene transfer to intro-
duce genes into Mk/plt progenitors derived from umbilical
cord blood. These relatively simple conditions resulted in
transduction of a variety of MK/plt progenitors as well as
mature platelets. The transduction efficiency of the large,
relatively mature CD341 cells that coexpressed either CD41
or CD61 was substantially higher than that of the smaller
more immature CD341 cells (compare Figures 3D and 3H
to 3C and 3G). Although it is common for the gene transfer
efficiency to be higher in relatively mature hematopoietic
cells, the reason for this in the current experiments remains
unclear [14]. All cell populations may have been transduced
at similar proportions with MN, but NGFR may have been
expressed more effectively in the relatively mature cells.
Alternatively, preferential transduction of the relatively
mature cells may have occurred due to upregulation of the
amphotropic MoMLV receptor by TPO and other
cytokines [24]. The high gene transfer efficiency in the rela-
tively mature MK/plt progenitors could also be related to
the relatively high levels of endomitosis in these cells.
Retroviral vector gene transfer occurs only in actively divid-
ing cells, leading some investigators to speculate that disso-
lution of the nuclear membrane during mitosis may be
required for entry of the retroviral core complex into the
nucleus [25]. Consequently, cells undergoing endomitosis
may not be absolutely dependent on cell division for retrovi-
ral vector gene transfer to occur. An improved understand-
ing of the reasons for the highly efficient transduction of the
relatively mature Mk/plt progenitors may provide insights
into processes that could enhance retroviral vector gene
transfer into more primitive multipotential stem cells.
At least two potential applications exist for the findings
described in this report. First, retroviral vector gene transfer
could be used to introduce genetic elements into Mk/plt pro-
genitors to study their biology or efficacy in disease-related
gene therapy strategies. For example, a variety of genes or
gene inhibitors such as antisense or dominant negative
mutants could be introduced into Mk/plt progenitors to elu-
cidate aspects of platelet development [26]. In addition,
genetic inhibitors of human immunodeficiency virus (HIV)
could be introduced into Mk/plt progenitors to determine
whether they mediate resistance to HIV infection and
whether they have any effect on platelet differentiation [27].
A second application involves gene-marking ex vivo
expanded MK/plt progenitors to determine whether they
contribute to more rapid platelet engraftment following
transplantation [28]. Recently, this approach has been tested
in a clinical trial involving the infusion of autologous ex vivo
expanded MK progenitors in persons undergoing peripheral
blood stem cell (PBSC) transplantation [29]. In this study,
PBSCs were mobilized with cyclophosphamide and granu-
locyte colony-stimulating factor (G-CSF), and then a por-
tion were cultured with a combination of cytokines. Signifi-
cant expansion of a variety of putative MK/plt progenitors
was observed, and infusion of the expanded cells caused no
adverse reactions. This study demonstrated the safety of this
approach; it did not demonstrate, however, whether the ex
vivo expanded Mk/plt progenitors contributed to platelet
engraftment. To address this issue, gene marking could be
used to unequivocally identify the contribution of the ex vivo
expanded cells to platelet engraftment. The gene marking
strategy described in this report indicates that it may be pos-
sible to identify the contribution of ex vivo expanded cells to
platelet engraftment by analyzing serial peripheral blood
samples following transplantation for the presence of
CD45–CD411NGFR1 platelets. In addition, bone marrow
could be sampled for the presence of NGFR1CFU-MK as
well as NGFR1CD341CD411 and CD341CD611 cells.
Concerns with this strategy include the possibility that the
NGFR marker protein may be immunogenic, although this
has not been observed in ongoing clinical trials involving
infusions of T cells transduced to express NGFR, possibly
because NGFR is a normal human protein [30]. In addition,
transplant recipients are substantially immunosuppressed
during the transplant process, further minimizing the
chances of immune rejection of NGFR-expressing cells.
Another concern is the possibility that NGFR expression
many interfere with cell growth, adversely affecting engraft-
ment of transduced cells. While this concern warrants fur-
ther evaluation, data have not been published to date that
indicate that this is a problem. Last, NGFR expression may
interfere with platelet aggregation and other functional
properties. While no evidence exists that this occurs, it
should be investigated systematically prior to using this gene
marking strategy in clinical trials.
In summary, the development of methods for expanding
and efficiently gene-marking UCB Mk/plt progenitors may
facilitate the evaluation of alternative ex vivo culture condi-
tions designed to overcome engraftment delay. In addition,
developing efficient methods for introducing genes into
Mk/plt progenitors may provide a powerful technique that
could be used in studying the molecular and cellular biology
of platelet development.
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